Then, CD147 glycosylation, which may be used as a marker to predict the clinical prognosis of cancer, represents a potential therapeutic target in cancers overexpressing the HG-CD147 form, and the development of new target-specific inhibitors for CD147 glycosylation could significantly improve the prognosis of cancer patients [27] (Table 1). Here, BSG is linked to cancer.